Chain Reaction Innovations, the entrepreneurship program at Argonne National Laboratory, is accepting applications for its next fellowship cohort.
Tiny antibodies in sharks have dexterity and flexibility that human antibodies do not. They can bind tightly to the spike proteins of coronaviruses and neutralize the virus. This could help researchers develop new vaccines and therapies for COVID-19.
Scientists from three national labs have published a comprehensive study that – alongside other recent, complementary studies of coronavirus proteins and genetics – represents the first step toward developing treatments for COVID-19.
Researchers have developed antibodies that can bind to phosphohistidine, an unstable molecule that’s linked to cancer. To learn how the two bind together, the team turned to the powerful X-rays at Argonne’s Advanced Photon Source. These new insights into its structure will help scientists design better antibodies for potential treatments.
An international team led by Empa and ETH Zurich researchers is playing with shape-engineered nanoscale building blocks that are up to 100-times larger than atoms and ions. And although these nano “Lego bricks” interact with each other with forces vastly different and much weaker than those holding atoms and ions together, they form crystals all by themselves, the structures of which resemble the ones of natural minerals. These new mega-crystals or superlattices that are depicted on the cover of the latest issue of “Nature” exhibit unique properties such as superfluorescence – and may well usher in a new era in materials science
For the first time, a team of researchers has captured X-ray images of a critical enzyme of the COVID-19 virus performing its function. This discovery could improve design of new treatments against the disease.
A team of biologists who banded together to support COVID-19 science determined the atomic structure of a coronavirus protein thought to help the pathogen evade and dampen response from human immune cells. The structural map has laid the groundwork for new antiviral treatments and enabled further investigations into how the newly emerged virus ravages the human body.
“Now, more than ever, with so many kids being at home, they need fun, hands-on scientific activities,” says Jason Benedict, contest founder, dad, and an associate professor of chemistry in the UB College of Arts and Sciences.
Researchers at the University of Alberta say a protease in SARS-CoV-2 can be targeted with a drug that is also used to treat feline infectious peritonitis, a fatal infection in cats caused by a coronavirus. The drugs, dipeptide-based protein inhibitors, could be used to slow or stop replication of the COVID-19 virus in humans. During the 70th annual meeting of the American Crystallographic Association, Joanne Lemieux will outline how the drugs are strong candidates for the treatment of human coronavirus infections.
Berkeley Lab’s Advanced Light Source X-ray facility has been recalled to action to support research related to COVID-19, the coronavirus disease that has already infected about 2 million people around the world.
Scientists and staff at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory are marshalling their expertise, unique facilities, and other key resources in the battle against COVID-19.
Argonne scientists are working around the clock to analyze the virus to find new treatments and cures, predict how it will propagate through the population, and make sure that our supply chains remain intact.